Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Phase 1

Completed

Conditions: Endometrial Cancer
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2013-06-26

Lead Sponsor: Beth Israel Deaconess Medical Center

Registration Number: NCT00004082

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Phase 3

Completed

Conditions: Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer
Bladder Cancer

First Posted Date: 2004-04-09

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 330

Registration Number: NCT00003376

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 47 locations

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00081302

Locations: 🇺🇸
Arlington Cancer Center - Arlington, Arlington, Texas, United States

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-04-06

Last Posted Date: 2019-02-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 23

Registration Number: NCT00002600

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa

First Posted Date: 2004-04-02

Last Posted Date: 2012-10-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 209

Registration Number: NCT00005798

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Halifax Medical Center, Daytona Beach, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-04-02

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003864

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 71 locations

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Ovarian Cancer
Sarcoma
Testicular Germ Cell Tumor
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Liver Cancer
Brain and Central Nervous System Tumors

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-02

Last Posted Date: 2020-02-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 21

Registration Number: NCT00007813

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

High-dose ICE With Amifostine

Phase 2

Completed

Conditions: Bladder Cancer
Brain and Central Nervous System Tumors
Carcinoma of Unknown Primary
Extragonadal Germ Cell Tumor
Head and Neck Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Sarcoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: Amifostine
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-03-31

Last Posted Date: 2017-01-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00003657

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-03-30

Last Posted Date: 2019-12-13

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 34

Registration Number: NCT00002974

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2004-03-17

Last Posted Date: 2013-04-10

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 7

Registration Number: NCT00006708

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States

and more 82 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy